Findings from Loyola University Chicago Broaden Understanding of Breast Cancer (Pleiotropic Anti-cancer Activities of Novel Non-covalent Thioredoxin Reductase Inhibitors Against Triple Negative Breast Cancer).

A recent study conducted at Loyola University Chicago focused on the potential of novel non-covalent thioredoxin reductase inhibitors in treating triple negative breast cancer (TNBC). The research highlighted the significance of targeting thioredoxin reductase 1 (TXNRD1) in TNBC therapy due to its higher levels in TNBC compared to normal tissue. The findings suggest that these inhibitors show promise in inhibiting TNBC cell viability and tumor growth, offering a new avenue for developing small molecule therapeutics for TNBC. The study was supported by various institutions and has been peer-reviewed, providing valuable insights into potential treatments for TNBC. [Extracted from the article]